Baseline characteristics of patients enrolled (13 patients)
| Characteristic . | Number . | |
|---|---|---|
| Age, median (range) | 56 (42-81) | |
| Women | 11 | |
| Histology | ||
| Adenocarcinoma | 11 | |
| NSCLC | 2 | |
| Smoking history | ||
| Never smokers | 7 | |
| ≤15 pack-y | 4 | |
| >15 pack-y | 2 | |
| Time from diagnosis of metastatic disease (mo) | ||
| Median (range) | 20 (8-91) | |
| Previous treatment | ||
| Erlotinib | 6 | |
| Gefitinib | 7 | |
| Time on erlotinib or gefitinib (mo) | ||
| Median (range) | 16 (8-79) | |
| EGFR | ||
| L858R* | 2 | |
| Exon 19 deletion | 6 | |
| Not available | 5 | |
| Characteristic . | Number . | |
|---|---|---|
| Age, median (range) | 56 (42-81) | |
| Women | 11 | |
| Histology | ||
| Adenocarcinoma | 11 | |
| NSCLC | 2 | |
| Smoking history | ||
| Never smokers | 7 | |
| ≤15 pack-y | 4 | |
| >15 pack-y | 2 | |
| Time from diagnosis of metastatic disease (mo) | ||
| Median (range) | 20 (8-91) | |
| Previous treatment | ||
| Erlotinib | 6 | |
| Gefitinib | 7 | |
| Time on erlotinib or gefitinib (mo) | ||
| Median (range) | 16 (8-79) | |
| EGFR | ||
| L858R* | 2 | |
| Exon 19 deletion | 6 | |
| Not available | 5 | |
On biopsy material obtained after treatment with gefitinib, one patient had both L858R and T790M.